Skip to main content
TITAN PHARMACEUTICALS INC logo

TITAN PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · TTNP ISIN · US8883146065 LEI · 549300NOUZGB2ZNVJ794 US Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2020-06-30 Declaration of Voting R…
Country US United States of America
Listing US TTNP

About TITAN PHARMACEUTICALS INC

https://www.titanpharm.com/

Titan Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that develops proprietary therapeutics using its clinically proven ProNeura® technology, a long-term, continuous drug delivery platform. This platform is designed for the administration of medicines to treat select chronic diseases. The ProNeura system involves a small, solid implant that is placed subdermally and provides continuous, non-fluctuating blood levels of a drug for an extended period. The company's development efforts have historically focused on treatments for central nervous system disorders.

Recent filings

Filing Released Lang Actions
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The key content is under Item 5.07, which relates to the submission of matters to a vote of security holders, specifically about a special meeting to approve an amendment to increase authorized shares. It discusses voting details, meeting adjournment, and the importance of the vote for financing operations. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports on shareholder voting matters. The document is not a full annual or quarterly report, nor a proxy solicitation or management discussion. It is a regulatory filing but specifically focused on voting results and rights announcements. Confidence is high given the clear match to Item 5.07 and voting-related content.
2020-06-30 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a co-promotion partnership agreement. It includes details about the agreement and references a press release as an exhibit. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The document is not a proxy, voting result, or management change announcement. It is a regulatory filing to inform the market of a significant business event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is 4601 characters, which is consistent with a typical 8-K filing. Confidence is high due to the clear identification of the form and content.
2020-06-25 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, specifically labeled as 'Definitive additional materials' related to a proxy solicitation for a special meeting of stockholders. It includes instructions for voting and contact information for proxy voting. There is no financial data, earnings information, or report content. The document is clearly proxy solicitation material, not a report or announcement of voting results. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is short and focused on voting instructions, consistent with PSI filings.
2020-06-19 English
DEF 14A
Proxy Solicitation & Information Statement
2020-05-22 English
FORM 10-Q
Interim / Quarterly Report Q1 2020
2020-05-15 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, as indicated by the header and form type PRE 14A. It is a solicitation of proxies for a special meeting of stockholders to approve an amendment to the certificate of incorporation to increase authorized shares. The text includes detailed information about the meeting, voting procedures, record date, and the proposal to increase authorized shares. It is not a report of financial results, earnings, or management discussion, nor is it a notice of voting results or a report publication announcement. The document is clearly a proxy solicitation material, which corresponds to the Proxy Solicitation & Information Statement category (PSI). The document length (15,000 characters) and content confirm it is the proxy statement itself, not just an announcement or a brief notice.
2020-05-12 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.